Will AI really kill us all, the $50b deal everyone's talking about & $1-a-day Ozempic

This week, Chanticleer columnists James Thomson and Anthony Macdonald try and sort out whether AI is actually going to kill us all, they take you in what might be the biggest ASX float in Australian history, and try to figure out what a $1-a-day dose of Ozempic might mean for the economy. 

This podcast is sponsored by Stripe

To ask a question, email chanticleer@afr.com.

Further reading:
One way or another, AI’s gods have hit trouble. Firmus isn’t immune
Concerns about AI are as surreal as the numbers on the neocloud’s float. And those are the two threats to the story: either it doesn’t work, or it works too damn well.
Bigger than BHP: Firmus will be Australia’s most capital-hungry beast
The party’s only just getting started for the capital arrangers, who have a new favourite client.
Migration mess comes back to the economy, stupid
The government’s migration changes reflect the business-like approach that the corporate sector has been calling for. But don’t expect the heat in this debate to fade.
Inside the eye-watering numbers Firmus is finally revealing to fundies
The neocloud hopeful is talking a huge game, but it takes a dive into the prospectus to get the full picture of its long-term ambitions and profit projections.
How $1-a-day Ozempic could unleash a $12b boom
The combination of GLP-1 drugs in pill form and expanded access via the Pharmaceutical Benefits Scheme could turbocharge adoption in Australia.

See omnystudio.com/listener for privacy information.